|Articles|July 20, 2017

Crohn's & Colitis Foundation Launches New IBD Clinical Trials Community

The Crohn's & Colitis Foundation announced the launch of a dedicated Clinical Trials Community for inflammatory bowel diseases (IBD). The community is designed to educate patients, caregivers, and healthcare providers about the clinical trial process, its value, and how to address barriers that exist in enrollment.

The Crohn's & Colitis Foundation's Clinical Trial Community is made possible by support from AbbVie, Celgene Corporation, Genentech, Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Crohn's & Colitis Foundation Launches New IBD Clinical Trials Community

Related Content

Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

A Shot in the Arm to Traditional Vaccine Trial Strategy